New
Global ETF Survey 2026: Answer now →
Help us improve your experience. Please confirm your investor type:
Global ETF Survey 2026
The ETF Industry Is Evolving Fast
From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.
XDNA ETF · iShares Genomics Immunology and Healthcare Index ETF
The XDNA Exchange Traded Fund (ETF) is provided by iShares. It is built to track an index: NYSE FactSet Global Genomics and Immuno Biopharma Index. The XDNA ETF provides physical exposure, so by buying it you actually own parts of all the 49 underlying holdings. This share class generates a stream of income by distributing dividends.
Last update Yesterday at 1:30 PM UTC
LIVE
CLOSED
This fund is part ofWorld Blended Cap1M perf.-1.58%
Last price
$49.75
1M perf.
+16.01%
1M flows
N/A
AuM
€5.3M
TER
0.44%
Rating
XDNA
$49.75
Performance & flows
Segment for quartile rank
March 30, 2026 → June 29, 2026
Create a free account to view the flows graph
XDNA
$49.43
+23.72%
World Blended Cap
+17.65%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | +16.01%  | +23.72% | +71.84% | +58.90%  | N/A | +16.01% | +19.49% | +33.30% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
More details
NAV
6/29/2026
$49.43
1D NAV change
+1.75%
Dividend policy
Replication method
Direct (Physical)
Replication model
Optimized sampling
No. of holdings
49
Inception date
4/26/2022
Jurisdiction
Canada
Distribution
Canada
Legal structure
Unit Trust
Base currency
CAD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Product type
Asset class
Factors
N/A
Investment strategy
The ETF has been designed to provide investors with exposure to the performance of an index, selected at the discretion of BlackRock, that is composed of companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. The current index for the ETF is the NYSE FactSet Global Genomics and Immuno Biopharma Index.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
New to Trackinsight?
For individual investors
Essentials
A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors
Enterprise
Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trialSimilar ETFs in your region
IDNA
1M perf.
+12.67%
TER
0.47%
2B78
1M perf.
+7.15%
TER
0.4%
LIV
1M perf.
+11.80%
TER
0.75%
MDEV
1M perf.
+3.32%
TER
0.7%
PJP
1M perf.
+8.52%
TER
0.57%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +23.72% | +71.84% | +58.90% | N/A |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise
Exposure
Countries
USA
59.58%
France
8.60%
Germany
7.82%
Japan
6.20%
Switzerland
5.98%
United Kingdom
3.99%
Denmark
3.14%
China
2.03%
Unavailable
0.30%
Other
2.36%
Sectors
Healthcare
99.70%
Unavailable
0.30%
Diversification
Total weight of top 15 holdings out of 49
Top 15 holdings
Data as of May 31, 2026
Create a free account to view top holdings
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise
Sustainability
Integrates ESG criteria
No
SDG
More sustainability metrics are available, exclusively in Trackinsight Enterprise
Replication
Trackinsight replication rating:
1-year trailing difference
As of May 29, 2026
Create a free account to view the replication graph
XDNA
N/A
Replication quality
Calculated over 12m, as of May 29, 2026
Tracking error
Tracking difference
1-year cumulative return difference
Best
Worst
Daily return difference
Average
Worst
Replication information
Index
Index ticker
Index dividend policy
Replication method
Replication model
Issuer
iShares
iShares ID Card
Number of funds
1778
Total AuM
€5.55T
Expense ratio range
0.03% - 1.51%
Average expense ratio
0.2832%
Top 5 funds by iShares
| AuM | ||
|---|---|---|
IVV | iShares Core S&P 500 ETF | €772.94B |
IEFA | iShares Core MSCI EAFE ETF | €162.99B |
IEMG | iShares Core MSCI Emerging Markets ETF | €138.9B |
CSSPX | iShares Core S&P 500 UCITS ETF | €130.24B |
IWDA | iShares Core MSCI World UCITS ETF | €122.79B |
Frequently asked questions about XDNA
What does iShares Genomics Immunology and Healthcare Index ETF, XDNA, invest in?
XDNA is a Passive ETF. This ETF provides exposure to Equities.
Which benchmark or index does XDNA replicate?
XDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma NR Index - CAD, through a optimized sampling replication method.
What is the Total Expense ratio (TER) of XDNA?
XDNA carries a total expense ratio (TER) of 0.44%, indicating the annual cost for holding the fund.
When was XDNA launched?
XDNA was introduced to the market on April 26, 2022. It trades on Canada
Who is the ETF issuer of XDNA?
iShares Genomics Immunology and Healthcare Index ETF, XDNA, is provided by iShares. Learn more about iShares here.
What is the current assets under management (AUM) of XDNA?
XDNA oversees €5.3M in assets as of June 29, 2026.
How has XDNA performed lately?
Based on data from June 29, 2026, XDNA returned 16.01% over the past month, 23.72% over the last three months and 33.30% year-to-date.
What are the latest inflows or outflows for XDNA?
As of June 29, 2026, XDNA recorded net flows of +€681K year-to-date.
Does XDNA distribute dividends?
XDNA follows a distributing dividend policy, meaning it pays out income to investors. As of June 29, 2026, its 12-month trailing yield was 0.24%.
What are the main country or region exposures of XDNA?
As of May 31, 2026, XDNA has significant geographic allocations in USA, France and Germany.
In which sector or theme does XDNA invest in?
As of May 31, 2026, XDNA focuses largely on Healthcare.
How many securities does XDNA hold and how diversified is it?
As of May 31, 2026, XDNA holds 49 positions in its portfolio, with 65.27% of assets concentrated in its top 15 holdings.
What are the main positions in XDNA?
As of May 31, 2026, XDNA top three holdings include Revolution Medicines, Inc., Moderna, Inc. and Ipsen SA.
What is the base currency of XDNA?
The base currency of XDNA is CAD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
